U.S. Public Health Service, Rockville, MD, USA; Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J Clin Lipidol. 2023 Mar-Apr;17(2):225-235. doi: 10.1016/j.jacl.2022.12.005. Epub 2022 Dec 24.
The American College of Cardiology/American Heart Association Blood Cholesterol Guideline was published in 2013 (2013 Cholesterol Guideline) and the Multi-society Guideline on the Management of Blood Cholesterol in 2018 (2018 Cholesterol Guideline).
To compare differences in population level estimates for statin recommendations and use between guidelines.
Using four 2-year cycles from the National Health and Nutrition Examination Survey (2011-2018), we analyzed data from 8,642 non-pregnant adults aged ≥20 years with complete information for blood cholesterol measurements and other cardiovascular risk factors used to define treatment recommendations in the 2013 or 2018 Cholesterol Guidelines. We compared the prevalence of statin recommendations and use between the guidelines, overall and among patient management groups.
Under the 2013 Cholesterol Guideline, an estimated 77.8 million (33.6%) adults would be recommended statins, compared to 46.1 million (19.9%) recommended and 50.1 million (21.6%) considered for statins by the 2018 Cholesterol Guideline. Statin use among those recommended treatment was similar utilizing the 2018 Cholesterol Guideline (47.4%) compared to the 2013 Cholesterol Guideline (47.0%). Differences were observed across demographic and patient management groups.
Compared to the 2013 Cholesterol Guideline, the prevalence of statin recommendations decreased utilizing the 2018 Cholesterol Guideline algorithm, though additional persons would be considered for treatment after risk factor assessment and patient-clinician discussion under the 2018 Cholesterol Guideline. Statin use was suboptimal (<50%) for those recommended treatment under either guideline. Optimizing patient-clinician risk discussions and shared decision making may be needed to improve treatment rates.
美国心脏病学会/美国心脏协会的血胆固醇指南于 2013 年发布(2013 年胆固醇指南),多学会 2018 年的血胆固醇管理指南(2018 年胆固醇指南)。
比较两个指南中他汀类药物推荐和使用的人群水平差异。
我们利用美国国家健康和营养调查(2011-2018 年)的四个两年周期,分析了来自 8642 名年龄≥20 岁、无妊娠且完整的血胆固醇测量和其他心血管危险因素数据的成年人,这些数据用于定义 2013 年或 2018 年胆固醇指南中的治疗建议。我们比较了这两个指南之间的他汀类药物推荐和使用的流行率,包括总体和不同患者管理组之间。
根据 2013 年胆固醇指南,估计有 7780 万人(33.6%)会被推荐使用他汀类药物,而根据 2018 年胆固醇指南,推荐使用他汀类药物的人数为 4610 万人(19.9%),考虑使用他汀类药物的人数为 5010 万人(21.6%)。在推荐接受治疗的人群中,使用他汀类药物的比例在 2018 年胆固醇指南下与 2013 年胆固醇指南下相似(分别为 47.4%和 47.0%)。在不同的人口统计学和患者管理组之间观察到了差异。
与 2013 年胆固醇指南相比,使用 2018 年胆固醇指南算法,他汀类药物的推荐率降低了,尽管在 2018 年胆固醇指南下,在进行危险因素评估和医患讨论后,会有更多的人被考虑接受治疗。根据任何一个指南,被推荐治疗的人群中,他汀类药物的使用都不理想(<50%)。可能需要优化医患风险讨论和共同决策,以提高治疗率。